FDA adds rare vision-loss warning to popular GLP-1 drugs
The FDA has added a new warning label to GLP-1 drugs, a class of popular medications used for weight loss that includes Ozempic and Wegovy. The warning alerts users to a rare side effect that can cause vision loss, sometimes permanently. This is the first time the FDA has required such a warning on these drugs.
24 across the spectrum. Choose a side on the bar to jump to it.
National story. 32 articles from 26 sources. 24 are on the bar; 2 are international, entertainment or tech outlets, listed separately. Updated 4h ago.
Left
7 sourcesTaking Ozempic or Wegovy? The FDA says there’s a new warning you shouldn’t ignore
FDA Says Popular GLP-1 Drugs Linked to Rare Risk of Vision Loss, Blindness
Center
12 sourcesTaking Ozempic or Zepbound? FDA orders warning about rare vision loss risk
What is NAION? Ozempic, Wegovy, other GLP-1s linked to rare eye condition
Right
5 sourcesFDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effects
GLP-1 drugs must have new warning label over incurable blindness condition, says FDA
Other outlets
International, entertainment and tech outlets, by their rating. Not counted in the bar above. How we count coverage
Left
2 articlesFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
Center
0 articlesNone
Right
0 articlesNone
The bigger story
This story is one of several related ones. Here's where it sits.